51 high-growth Healthcare stocks rated Buy or better (Nov 2026)
51 high-growth Healthcare stocks rated Buy or better by the Lician Quant rating as of Nov 4, 2026, including BeOne Medicines Ltd. (ONC), Natera Inc (NTRA), Guardant Health Inc (GH). Growth grade A- or better (revenue, EPS and free-cash-flow growth against sector peers) and a Buy or Strong Buy rating.
Open this screen in the full screener to add filters, sort by any factor and save it.
51 stocks · Strong Buy or Buy · Healthcare · Growth ≥ A-
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1IBRXImmunitybio Inc | 3.52Buy | F | A+ | D | B- | A | $8.7B | NM | +192.9% | — | 31.2% | — |
| 2LQDALiquidia Technologies Inc | 4.15Buy | B | A+ | A+ | C | F | $3.8B | 27.4 | +2,234% | — | 26.1% | — |
| 3CRMDCorMedix Inc | 4.14Buy | A+ | A+ | A+ | F | D- | $579M | 3.1 | — | — | 22.0% | Nov 11 |
| 4TGTXTG Therapeutics Inc | 4.43Buy | C+ | A+ | A | A+ | F | $8.1B | 18.4 | +76.1% | — | — | — |
| 5MGTXMeiraGTx Holdings PLC | 4.82Strong Buy | A | A+ | A+ | D | B- | $897M | 11.4 | +948.3% | — | 17.6% | Nov 12 |
| 6TARSTarsus Pharmaceuticals Inc | 3.73Buy | D | A+ | C+ | C+ | C+ | $3.1B | NM | +105.2% | — | — | — |
| 7ARQTArcutis Biotherapeutics Inc | 4.92Strong Buy | C+ | A+ | A- | A- | B+ | $3.9B | 137.4 | +76.1% | — | 23.9% | Nov 4 |
| 8ZVRAZevra Therapeutics Inc. | 4.59Strong Buy | A- | A+ | A+ | C | D+ | $582M | 10.0 | +119.4% | — | — | — |
| 9FENCFennec Pharmaceuticals Inc | 3.64Buy | D | A+ | B- | A- | D- | $360M | NM | +77.8% | — | 3.4% | Nov 12 |
| 10BCYCBicycle Therapeutics Ltd | 4.04Buy | B+ | A+ | D+ | D | A- | $257M | NM | +194.7% | — | 183.3% | — |
| 11ETONEton Pharmaceuticals Inc | 4.80Strong Buy | D+ | A+ | A- | A- | A- | $1.4B | 113.6 | +81.5% | — | 9.3% | Nov 5 |
| 12DCTHDelcath Systems Inc | 4.73Strong Buy | C+ | A+ | B | B | A- | $499M | 938.8 | +35.8% | — | 6.6% | Nov 9 |
| 13KNSAKiniksa Pharmaceuticals Ltd | 4.89Strong Buy | B- | A+ | A | A+ | C | $4.1B | 37.7 | +58.2% | — | 9.6% | — |
| 14BCRXBioCryst Pharmaceuticals Inc | 3.58Buy | D+ | A+ | C | C | B- | $2.1B | NM | +68.7% | — | 12.8% | Nov 4 |
| 15RNAAtrium Therapeutics, Inc. Common Stock | 3.61Buy | B- | A+ | F | D | A+ | $141M | NM | +235.3% | — | — | Nov 12 |
| 16OSCROscar Health Inc | 4.97Strong Buy | — | A | A- | A | B- | — | — | +42.8% | — | — | Nov 5 |
| 17TMDXTransMedics Group Inc | 3.78Buy | B+ | A | A- | F | D+ | $2.3B | 15.3 | +25.8% | — | — | Nov 5 |
| 18SENSSenseonics Holdings, Inc. Common Stock | 4.06Buy | D+ | A | F | A- | A+ | $391M | NM | +90.6% | — | — | Nov 9 |
| 19ASTHAstrana Health Inc | 4.93Strong Buy | A+ | A | B | C | A+ | $1.8B | 44.0 | +58.9% | — | 8.0% | Nov 5 |
| 20ONCBeOne Medicines Ltd. | 4.11Buy | F | A | A | B- | — | $522B | 795.5 | +34.3% | — | — | Nov 5 |
| 21NTRANatera Inc | 3.68Buy | F | A | C+ | A | C- | $58.0B | NM | +37.8% | — | — | Nov 5 |
| 22STIMNeuronetics Inc | 3.88Buy | C- | A | D+ | C | A | $166M | NM | +39.6% | — | — | Nov 4 |
| 23BWAYBrainsway Ltd. | 3.86Buy | C+ | A | B+ | D- | — | $447M | 59.1 | +27.3% | — | — | Nov 10 |
| 24ANIPANI Pharmaceuticals Inc | 4.67Strong Buy | A+ | A | A | D | C+ | $1.6B | 14.8 | +30.9% | — | 22.7% | Nov 5 |
| 25GHGuardant Health Inc | 3.61Buy | F | A | C- | A- | B- | $23.9B | NM | +42.7% | — | 9.8% | Nov 5 |
Showing 25 of 51
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar
Top growth in other sectors
About this screen
- Which are the top high-growth Healthcare stocks rated Buy or better?
- As of Nov 4, 2026, the highest ranked are Immunitybio Inc (IBRX, rating 3.52); Liquidia Technologies Inc (LQDA, rating 4.15); CorMedix Inc (CRMD, rating 4.14); TG Therapeutics Inc (TGTX, rating 4.43); MeiraGTx Holdings PLC (MGTX, rating 4.82). 51 stocks pass the screen in total.
- What does this screen look for?
- Growth grade A- or better (revenue, EPS and free-cash-flow growth against sector peers) and a Buy or Strong Buy rating.
- How is the Lician Quant rating calculated?
- Each stock gets five factor grades (Valuation, Growth, Profitability, Momentum, EPS Revisions) from A+ to F by ranking its metrics against the other stocks in its sector. The rating (1.00 to 5.00) is the equal-weight average of the factor scores, re-ranked within the sector: 4.50 and up is Strong Buy, 3.50 Buy, 2.50 Hold, 1.50 Sell, below that Strong Sell.
- How often is the list updated?
- After every US trading day, from SEC filings, EODHD prices and analyst estimates; this list is from the quant run of Nov 4, 2026. Short interest follows FINRA's twice-monthly settlement dates.